Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ibrutinib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 34 for your search:
Start Over
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR101862, PCI-32765MCL4001, NCT01833039
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1112-CA, 2012-000694-23, NCT01578707
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100840, PCI-32765CLL3001, 2012-000600-15, U1111-1135-3745, NCT01611090
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100848, PCI-32765MCL3001, 2012-000601-74, U1111-1135-6930, NCT01646021
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)
Phase: Phase III
Type: Treatment
Status: Enrolling by invitation
Age: 65 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1116-CA, 2012-003968-44, NCT01724346
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 65 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100967, PCI-32765MCL3002, U1111-1137-0389, 2012-004056-11, NCT01776840
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase: Phase III
Type: Treatment
Status: Enrolling by invitation
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100955, 2012-004225-24, PCI-32765CAN3001, NCT01804686
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1102-CA, PCI-32765, NCT01105247
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1109-CA, PCI-32765, NCT01217749
Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 65 and over
Sponsor: Other
Protocol IDs: 2012-0086, NCI-2013-00029, NCT01752426
Ublituximab + Ibrutinib in Select B-cell Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Enrolling by invitation
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: UTX-IB-104, NCT02013128
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Enrolling by invitation
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1103-CA, PCI-32765, NCT01109069
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1104-CA, PCI-32765, NCT01236391
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1106-CA, PCI-32765, NCT01325701
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1111-CA, PCI-32765, NCT01478581
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NHLBI
Protocol IDs: 120035, 12-H-0035, NCT01500733
Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0785, NCI-2012-00126, NCT01520519
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-11133, NCI-2012-00560, NCT01589302
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100847, PCI-32765MCL2001, 2012-000711-88, NCT01599949
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-015, NCT01614821
A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1117-CA, 2012-004476-19, NCT01744691
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100956, 2012-004097-26, PCI-32765FLR2002, NCT01779791
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00887, MC1282, 9271, N01CM00032, N01CM00099, P30CA015083, NCT01849263
Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0090, NCI-2013-01304, NCT01880567
Start Over